SCHEMBL14199913

SCHEMBL14199913

Cc1ccc(C(=O)Nc2ccc(CO)cc2)c([N+](=O)[O-])c1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.53
▸ KMT2A Q03164 8/20 0.53
▸ MAPT P10636 6/20 0.52
▸ MAPK1 P28482 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ GPR55 Q9Y2T6 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ GAA P10253 2/20 0.45
▸ SGMS2 Q8NHU3 1/20 0.45
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ PKM P14618 1/20 0.44
▸ SENP5 Q96HI0 1/20 0.43
▸ SENP2 Q9HC62 1/20 0.43
▸ SENP1 Q9P0U3 1/20 0.43
▸ PPIA P62937 1/20 0.42
▸ FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12779412 0.90 SENP5 (0.49) MEN1KMT2AMAPTMAPK1ALDH1A1
SCHEMBL14199904 0.88 MEN1 (0.52) MEN1KMT2AMAPTMAPK1ALDH1A1
SCHEMBL12778249 0.84 MEN1 (0.47) MEN1KMT2AMAPTMAPK1ALDH1A1
SCHEMBL12253970 0.82 PTPN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2PKM
SCHEMBL12779413 0.82 MEN1 (0.47) MEN1KMT2AMAPTMAPK1ALDH1A1
SCHEMBL14199914 0.80 HPGD (0.47) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL14450789 0.78 HPGD (0.47) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12253971 0.78 ALDH1A1 (0.46) KMT2AMAPTMAPK1ALDH1A1RAB9A
SCHEMBL14199912 0.78 HPGD (0.46) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12253976 0.76 SIGMAR1 (0.45) MAPTALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 — — US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 MEN1 4301/4885KMT2A 2424/4885MAPT 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback